Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 6:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Celecoxib 100 mg Clear all
Terminated Phase 4 Interventional Results available

Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.

NCT00484718
View directory record Official record
Conditions
Osteoarthritis
Interventions
celecoxib, Oxycodone, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 3 Interventional Results available

Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat

NCT00402987
View directory record Official record
Conditions
Pharyngitis
Interventions
celecoxib, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 18 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor

NCT00314262
View directory record Official record
Conditions
Precancerous Conditions
Interventions
Erlotinib & Celecoxib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 3 Interventional

Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007

NCT02301234
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg, Celecoxib 100 mg, Celecoxib 100 mg Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
32
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 1 Interventional

CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)

NCT00346801
View directory record Official record
Conditions
Lung Cancer
Interventions
Celecoxib, Cisplatin, CPT-11, Concurrent Thoracic Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2012 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 2 Interventional Results available

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

NCT00061893
View directory record Official record
Conditions
Sarcoma
Interventions
celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, conventional surgery, radiation therapy, MESNA, Filgrastim
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 10, 2026, 6:18 PM EDT
Active, not recruiting Phase 2 Interventional

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine
Drug · Biological
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Davis, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 10, 2026, 6:18 PM EDT
Active, not recruiting Phase 2 Interventional

Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

NCT02574728
View directory record Official record
Conditions
Cancer
Interventions
Sirolimus, Celecoxib, Etoposide, Cyclophosphamide
Drug
Lead sponsor
Emory University
Other
Eligibility
12 Months to 30 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
6
States / cities
Phoenix, Arizona • Wilmington, Delaware • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 2 Interventional

Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis

NCT00355576
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Celecoxib, Creatine, Minocycline
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 85 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2011 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 4 Interventional

A Study Of Opioid Avoidance In Surgery Through Integrating Suzetrigine

NCT07257133
View directory record Official record
Conditions
Post Operative Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of NSAIDs on Bone Metabolism Following Exercise

NCT05512013
View directory record Official record
Conditions
Bone Resorption, Stress Fracture, Bone Injury
Interventions
Ibuprofen 800 mg, Celecoxib 200mg, Flurbiprofen 100 mg, Placebo
Drug
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 42 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 2 Interventional Results available

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

NCT03084536
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Cancer of Breast
Interventions
Bupivacaine, Gabapentin, Celecoxib, Acetaminophen, Midazolam, Fentanyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis

NCT00154219
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Lumiracoxib (drug)
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure

NCT00624559
View directory record Official record
Conditions
Hypertension
Interventions
celecoxib (Celebrex), Placebo
Drug · Other
Lead sponsor
University of Delaware
Other
Eligibility
22 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Sep 10, 2026, 6:18 PM EDT
Terminated Phase 3 Interventional Results available

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

NCT00809354
View directory record Official record
Conditions
Osteoarthritis, Arthritis
Interventions
NSAID, tanezumab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
250
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 161 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 2 Interventional Results available

Open-Label CA-008 (Vocacapsaicin) in Bunionectomy

NCT03885596
View directory record Official record
Conditions
Pain
Interventions
CA-008, Ketorolac, Acetaminophen IV, Fentanyl, Bupivacaine Hydrochloride, Lidocaine HCl, Celecoxib, Acetaminophen Oral, Lidocaine Hydrochloride, Exparel
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Sep 10, 2026, 6:18 PM EDT
Not yet recruiting Phase 2 Interventional

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

NCT07634094
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure
Drug · Biological · Procedure
Lead sponsor
Kalinski, Pawel, MD, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 10, 2026, 6:18 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

NCT03686657
View directory record Official record
Conditions
Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
Interventions
Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High
Drug
Lead sponsor
ARKAY Therapeutics
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 2 Interventional Results available

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

NCT00357500
View directory record Official record
Conditions
Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
celecoxib, cyclophosphamide, etoposide, fenofibrate, thalidomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 21 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Results available

Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

NCT00346216
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
celecoxib, Ibuprofen, Naproxen
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
24,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
871
States / cities
Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 515 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 3 Interventional Results available

Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.

NCT03108482
View directory record Official record
Conditions
Acute Post-surgical Pain
Interventions
Co-crystal E-58425 (Tramadol/Celecoxib), Tramadol (Ultram®), Celecoxib (Celebrex®), Placebo
Drug
Lead sponsor
Esteve Pharmaceuticals, S.A.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Sep 10, 2026, 6:18 PM EDT
Completed Phase 1 Interventional

Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2

NCT00400374
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Erlotinib, Celecoxib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Sep 10, 2026, 6:18 PM EDT
Withdrawn Phase 3 Interventional

Multimodal Analgesia in Shoulder Arthroplasty

NCT03586934
View directory record Official record
Conditions
Shoulder Pain, Opioid Use
Interventions
Acetaminophen, Celecoxib 200mg, Celecoxib 400 mg, Ropivacaine, Ketorolac, Acetaminophen Injectable Product, Oxycodone, Tramadol, Morphine Injectable Solution, hydrocodone bitartrate and acetaminophen, Morphine, Oxycodone Hydrochloride, Meloxicam
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 10, 2026, 6:18 PM EDT